» Articles » PMID: 39596385

The Role of Gut Microbiota in the Onset and Progression of Obesity and Associated Comorbidities

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Nov 27
PMID 39596385
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity, a global public health problem, is constantly increasing, so the concerns in preventing and combating it are increasingly focused on the intestinal microbiota. It was found that the microbiota is different in lean people compared to obese individuals, but the exact mechanisms by which energy homeostasis is influenced are still incompletely known. Numerous studies show the involvement of certain bacterial species in promoting obesity and associated diseases such as diabetes, hypertension, cancer, etc. Our aim is to summarize the main findings regarding the influence of several factors such as lifestyle changes, including diet and bariatric surgery, on the diversity of the gut microbiota in obese individuals. The second purpose of this paper is to investigate the potential effect of various microbiota modulation techniques on ameliorating obesity and its comorbidities. A literature search was conducted using the PubMed database, identifying articles published between 2019 and 2024. Most studies identified suggest that obesity is generally associated with alterations of the gut microbiome such as decreased microbial diversity, an increased Firmicutes-to-Bacteroidetes ratio, and increased SCFAs levels. Our findings also indicate that gut microbiota modulation techniques could represent a novel strategy in treating obesity and related metabolic diseases. Although some mechanisms (e.g., inflammation or hormonal regulation) are already considered a powerful connection between gut microbiota and obesity development, further research is needed to enhance the knowledge on this particular topic.

Citing Articles

The Role of the Gut Microbiota in Health, Diet, and Disease with a Focus on Obesity.

Ma Z, Lee Y Foods. 2025; 14(3).

PMID: 39942085 PMC: 11817362. DOI: 10.3390/foods14030492.


Impact of Enzymatic Degradation Treatment on Physicochemical Properties, Antioxidant Capacity, and Prebiotic Activity of Lilium Polysaccharides.

Peng K, Zhang Y, Zhang Q, Wang Y, Liu Y, Cui X Foods. 2025; 14(2.

PMID: 39856913 PMC: 11765260. DOI: 10.3390/foods14020246.


Polyunsaturated Fatty Acids and Human Health: A Key to Modern Nutritional Balance in Association with Polyphenolic Compounds from Food Sources.

Mititelu M, Lupuliasa D, Neacsu S, Olteanu G, Busnatu S, Mihai A Foods. 2025; 14(1.

PMID: 39796335 PMC: 11719865. DOI: 10.3390/foods14010046.

References
1.
Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj J, Milagro F, Martinez J . Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications. Adv Nutr. 2019; 10(suppl_1):S17-S30. PMC: 6363528. DOI: 10.1093/advances/nmy078. View

2.
Ionescu R, Enache R, Cretoiu S, Gaspar B . Gut Microbiome Changes in Gestational Diabetes. Int J Mol Sci. 2022; 23(21). PMC: 9654708. DOI: 10.3390/ijms232112839. View

3.
Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L . The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011; 8(2):110-20. PMC: 4003137. DOI: 10.1038/cmi.2010.67. View

4.
Davis C . The Gut Microbiome and Its Role in Obesity. Nutr Today. 2016; 51(4):167-174. PMC: 5082693. DOI: 10.1097/NT.0000000000000167. View

5.
Leeuwendaal N, Cryan J, Schellekens H . Gut peptides and the microbiome: focus on ghrelin. Curr Opin Endocrinol Diabetes Obes. 2021; 28(2):243-252. PMC: 7924980. DOI: 10.1097/MED.0000000000000616. View